Esperion Therapeutics Inc (NAS:ESPR)
$ 2.22 -0.07 (-3.06%) Market Cap: 420.60 Mil Enterprise Value: 478.14 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 55/100

Esperion Therapeutics Inc at Bank of America Global Healthcare Conference Transcript

May 11, 2023 / 03:40PM GMT
Release Date Price: $1.49 (+2.05%)
Jason Eron Zemansky
BofA Securities, Research Division - VP

My name is Jason Zemansky. I'm one of the new SMID-cap analyst here at BofA. I'd like to welcome you to the final morning of our 2023 Healthcare Conference.

Very pleased this morning to be introducing Sheldon Koenig, President and CEO of Esperion Pharmaceuticals. His first, I believe, conference pending -- following the dispute.

Questions & Answers

Jason Eron Zemansky
BofA Securities, Research Division - VP

So I think why don't we just dive in? And let me ask, maybe to start things off, a question on most investors' minds. I appreciate things are a little in flux and there are some restrictions here. But can you provide a little color on what's going on thus far with the lawsuit and maybe potential time lines for resolution?

Sheldon L. Koenig
Esperion Therapeutics, Inc. - President, CEO & Director

Yes. Great. So first of all, Jason, thank you very much on behalf of all the employees of Esperion. We really appreciate the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot